FDA seeks public input on ibogaine trials

FDA seeks public input on ibogaine trials

The U.S. Food and Drug Administration (FDA) has announced a call for public input on the design of government-funded clinical trials for ibogaine, a psychoactive compound under investigation for treating opioid use disorder and PTSD. This request, made public on October 5, 2023, is part of the FDA's effort to gather comprehensive data on the safety and efficacy of ibogaine, which is derived from the West African shrub Tabernanthe iboga.

Michael Davis, director of the FDA Center for Drug Evaluation and Research, emphasized the need for rigorous scientific evaluation of ibogaine, acknowledging its potential but also its "serious safety concerns," particularly cardiac risks. The FDA is soliciting comments on various aspects of ibogaine studies, including safety, dosage, and ethical considerations, with a deadline for submissions set for November 20, 2026.

Gabon's strategic move in the ibogaine market

Gabon, home to the iboga shrub, is taking steps to protect its natural resources and benefit financially from the growing international interest in ibogaine. According to a report by Mongabay, the Gabonese government has adopted measures to regulate the trade of iboga and its derivatives. This includes a draft decree to ban iboga exports and a presidential decree signed by President Brice Oligui Nguema in May 2023 to assert control over the plant and its traditional uses.

Georges Gassita, a Gabonese civil servant, noted a significant increase in the price of iboga seedlings, reflecting heightened demand following a U.S. executive order promoting psychedelic research. Gabon's strategy includes seeking royalties from international patents and synthetic ibogaine sales, aiming to channel these revenues into national development.

Why it matters

The FDA's initiative to involve public opinion in ibogaine trials underscores the complexity and potential of psychedelic treatments for serious health conditions. By addressing safety concerns and ethical considerations, the FDA aims to ensure that ibogaine, if proven effective, is safely integrated into treatment protocols.

Simultaneously, Gabon's proactive stance highlights the geopolitical and economic dimensions of the psychedelic industry. As the birthplace of iboga, Gabon's efforts to secure a share of the ibogaine market could set a precedent for other countries with native psychedelic plants.

These developments reflect a broader trend of increasing interest and investment in psychedelic research and its potential therapeutic applications.